Lourdes Riquelme, Author at Labiotech.eu

About

Spanish Biotechnologist with a MS in Genetics from Universidad Autonoma of Barcelona. My interests go from science to fashion and anything in between.

Articles by Lourdes Riquelme

News and Trends 12 Mar 2015

Alderley Park Life Science Campus, on the go

Manchester Science Partnerships (MSP) and Bruntwood have revealed plans for the first phase of development at their flagship 162-hectare life science campus at Alderley Park, Cheshire. The plans centered on the Mereside science campus and were revealed at MIPIM – the annual international property conference held in Cannes, France. The session, titled ‘Translating Science into […]

March 12, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 12 Mar 2015

Bioluminescent Bacteria and Algae, the Future Lighting

The University of Sevilla has patented a method for culturing the bacteria Vibrio fischeri and the algae Pyrocystus fusiformis in order to configure bioluminescent devices that emit light without electricity consumption, with applications in environmental lighting and signaling. Bioluminescence is a widespread phenomenon at all biological levels (bacteria, fungi, worms, insects, etc.). It consists of […]

March 12, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 11 Mar 2015

First Treatment Approved under Early Access to Medicine Scheme (EAMS)

Today, it has been accepted! The first drug approved through the Early Access to Medicine Scheme (EAMS), named pembrolizumab, is an immunotherapy treatment for advanced melanoma. The treatment has been developed by Merck, known as MSD outside the United States and Canada, with early development work carried out using MRC Technology’s antibody humanization expertise. EAMS is […]

March 11, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 11 Mar 2015

Vitic database, the new must-have tool

The latest version of the Vitic Intermediates database, chemical database and information management system, has been released by Lhasa Limited, a leading global supplier of knowledge based software and associated databases. Initiated in 2006, Vitic Intermediates is a cross industry data sharing consortium created and co-ordinated by Lhasa Limited, through the Vitic Nexus platform, supported by […]

March 11, 2015 - 3 minutesmins - By Lourdes Riquelme

Philosophical Transactions 350 anniversary

News and Trends 10 Mar 2015

350th anniversary of Philosophical Transactions, the first scientific journal

The world’s oldest continuously published journal, Philosophical Transactions of the Royal Society of London (RSL), celebrates its 350th anniversary on 6 March 2015. Academic journals are the cornerstone of science research. They serve as showcases, forums where researchers present their discoveries to the scientific community so they can be scrutinized, criticized and confirmed or rejected. […]

March 10, 2015 - 3 minutesmins - By Lourdes Riquelme

News and Trends 9 Mar 2015

MorphoSys and Emergent BioSolutions Initiate Phase I

MorphoSys AG and Emergent BioSolutions will initiate a Phase I clinical study to evaluate the safety, tolerability, and clinical activity of MOR209/ES414 in patients with metastatic castration-resistant prostate cancer (mCRPC). A few months ago, we talked about the beginning of the collaboration between MorphoSys and Emergent BioSolutions. Now, the fruit of their combined work, an […]

March 9, 2015 - 3 minutesmins - By Lourdes Riquelme

News and Trends 7 Mar 2015

New insights into drought tolerance in plants

Spanish researchers found a new family of proteins that controls plant resistance to drought. The work will allow the design of crop plants with improved properties over this type of stress. Two teams of the Spanish National Research Council (CSIC in Spanish) have identified and characterized a new protein family that directly controls the drought […]

March 7, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 6 Mar 2015

Novartis achieves the First Biosimilar approval in US

The Novartis company Sandoz has become the first company with a biosimilar approved by the US Food and Drug Administration (FDA) after today’s approval of Zarxio, a treatment for neutropenia. Sandoz is the first company to receive the approval of a biosimilar in the US through the new FDA biosimilars pathway established under Biologics Price […]

March 6, 2015 - 3 minutesmins - By Lourdes Riquelme

News and Trends 6 Mar 2015

Petunica circadia, where Art and Biotechnology meet

A changing-color flower that goes from blue to red and viceversa? It may sound like science fiction, but it’s purely biotechnology. A simple petunia to make a statement: gene engineering is not something to be afraid of. Biotechnology has so many applications that go from nourishing the increasing world population to growing beautiful flowers to […]

March 6, 2015 - 3 minutesmins - By Lourdes Riquelme

News and Trends 5 Mar 2015

Synpromics and UniQure, new Collaboration in Gene Therapy.

Synpromics has formed a collaboration with uniQure, the Dutch pioneer in human gene therapy, to develop synthetic promoters with specific application in the delivery of gene therapies to liver. Synpromics, a leading synthetic biology company, will use its unique approach to develop synthetic promoters with upregulated, liver cell specific, activity whilst also decreasing the promoter molecular […]

March 5, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 5 Mar 2015

Baxter’s Bioscience Business Acquires SuppreMol

Baxter has acquired SuppreMol for €200M before working capital and other adjustments. The acquisition includes SuppreMol’s early-stage development portfolio of novel biologic immunoregulatory therapeutics for the treatment of autoimmune diseases. SuppreMol is a privately held biopharmaceutical company based in Martinsried, Germany developing treatment options for autoimmune and allergic diseases, focusing on the modulation of Fc […]

March 5, 2015 - 2 minutesmins - By Lourdes Riquelme

Bavarian Nordic Bristol Myers Squibb cancer

News and Trends 4 Mar 2015

Bristol-Myers Squibb signs an agreement for Bavarian Nordic’s PROSTVAC

Bristol-Myers Squibb signs an exclusive agreement with Bavarian Nordic for PROSTVAC, a prostate-specific antigen-targeting cancer immunotherapy. Bavarian Nordic will receive up to €880.4M. Bristol-Myers Squibb will have the exclusive option to license and commercialize PROSTVAC, Bavarian Nordic’s investigational Phase III prostate-specific antigen (PSA) in development for the treatment of asymptomatic or minimally symptomatic metastatic castration-resistant […]

March 4, 2015 - 2 minutesmins - By Lourdes Riquelme

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Lourdes Riquelme

About

Articles by Lourdes Riquelme

Alderley Park Life Science Campus, on the go

Bioluminescent Bacteria and Algae, the Future Lighting

First Treatment Approved under Early Access to Medicine Scheme (EAMS)

Vitic database, the new must-have tool

350th anniversary of Philosophical Transactions, the first scientific journal

MorphoSys and Emergent BioSolutions Initiate Phase I

New insights into drought tolerance in plants

Novartis achieves the First Biosimilar approval in US

Petunica circadia, where Art and Biotechnology meet

Synpromics and UniQure, new Collaboration in Gene Therapy.

Baxter’s Bioscience Business Acquires SuppreMol

Bristol-Myers Squibb signs an agreement for Bavarian Nordic’s PROSTVAC

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

About

Articles by Lourdes Riquelme

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!